Last reviewed · How we verify

Six percent hydroxy ethyl starch 130/0.4

Rajaie Cardiovascular Medical and Research Center · Phase 3 active Small molecule

Six percent hydroxy ethyl starch 130/0.4 is a Synthetic colloid / Volume expander Small molecule drug developed by Rajaie Cardiovascular Medical and Research Center. It is currently in Phase 3 development for Fluid resuscitation in acute blood loss and hypovolemia, Perioperative volume management in cardiovascular surgery.

Hydroxyethyl starch (HES) 130/0.4 is a synthetic colloid that expands intravascular volume by increasing plasma oncotic pressure and maintaining fluid in the vascular space.

Hydroxyethyl starch (HES) 130/0.4 is a synthetic colloid that expands intravascular volume by increasing plasma oncotic pressure and maintaining fluid in the vascular space. Used for Fluid resuscitation in acute blood loss and hypovolemia, Perioperative volume management in cardiovascular surgery.

At a glance

Generic nameSix percent hydroxy ethyl starch 130/0.4
SponsorRajaie Cardiovascular Medical and Research Center
Drug classSynthetic colloid / Volume expander
ModalitySmall molecule
Therapeutic areaCardiovascular / Critical Care
PhasePhase 3

Mechanism of action

HES 130/0.4 is a third-generation synthetic colloid composed of hydroxyethyl starch with a molecular weight of 130 kDa and degree of substitution of 0.4. It functions as a volume expander used in fluid resuscitation, maintaining intravascular volume and improving microcirculation by virtue of its colloid osmotic properties. The 6% concentration provides a balanced approach to plasma volume expansion with reduced risk of hyperchloremic acidosis compared to earlier HES formulations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Six percent hydroxy ethyl starch 130/0.4

What is Six percent hydroxy ethyl starch 130/0.4?

Six percent hydroxy ethyl starch 130/0.4 is a Synthetic colloid / Volume expander drug developed by Rajaie Cardiovascular Medical and Research Center, indicated for Fluid resuscitation in acute blood loss and hypovolemia, Perioperative volume management in cardiovascular surgery.

How does Six percent hydroxy ethyl starch 130/0.4 work?

Hydroxyethyl starch (HES) 130/0.4 is a synthetic colloid that expands intravascular volume by increasing plasma oncotic pressure and maintaining fluid in the vascular space.

What is Six percent hydroxy ethyl starch 130/0.4 used for?

Six percent hydroxy ethyl starch 130/0.4 is indicated for Fluid resuscitation in acute blood loss and hypovolemia, Perioperative volume management in cardiovascular surgery.

Who makes Six percent hydroxy ethyl starch 130/0.4?

Six percent hydroxy ethyl starch 130/0.4 is developed by Rajaie Cardiovascular Medical and Research Center (see full Rajaie Cardiovascular Medical and Research Center pipeline at /company/rajaie-cardiovascular-medical-and-research-center).

What drug class is Six percent hydroxy ethyl starch 130/0.4 in?

Six percent hydroxy ethyl starch 130/0.4 belongs to the Synthetic colloid / Volume expander class. See all Synthetic colloid / Volume expander drugs at /class/synthetic-colloid-volume-expander.

What development phase is Six percent hydroxy ethyl starch 130/0.4 in?

Six percent hydroxy ethyl starch 130/0.4 is in Phase 3.

What are the side effects of Six percent hydroxy ethyl starch 130/0.4?

Common side effects of Six percent hydroxy ethyl starch 130/0.4 include Hyperchloremic acidosis, Acute kidney injury, Coagulopathy, Increased transfusion requirements, Allergic reactions.

Related